-
-
-
-
-
-
-
Immuneering reports 17.3-month survival in pancreatic cancer trial
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Tops Q3 EPS by 3c
-
-
-
-
-
-
-
Oppenheimer on Immuneering Corporation (IMRX): 'we believe there's additional upside with this upcoming catalyst'
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Reports Positive Overall Survival Data for Atebimetinib
-
-
-
-
-
-
-
Morgan Stanley Downgrades Immuneering Corporation (IMRX) to Underweight
-
-
-
-
-
-
-
Mizuho Reiterates Neutral Rating on Immuneering Corporation (IMRX)
432,376 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

